Atossa Therapeutics, Inc. (ATOS) Stock

Atossa Therapeutics, Inc. (ATOS) is a Healthcare stock trading at $2.54 (as of 2026-08-21), with a market capitalization of $25.30M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.

Understand Atossa Therapeutics, Inc.: how it makes money

Atossa Therapeutics develops biopharmaceutical drug candidates for unmet needs in oncology for women breast cancer, including oral (Z)-endoxifen in Phase II trials, and it also develops immunotherapy and CAR-T programs. The provided facts do not describe the specific revenue streams it uses to make money.

The profit model is driven by clinical and IP progress in its oncology programs, with results like Primary Endpoint Achievement Rate and newly granted US patent coverage for Z-endoxifen indicating whether the company can advance (and ultimately commercialize) its candidates.

Business quality (Weak): The provided facts depict an early-stage, clinical-development company, with deeply negative operating profitability and no reported revenue for the latest period, while key program metrics (endpoints and trial outcomes) show measurable progress alongside safety data.

Bull case

  • Clinical progress signal in breast cancer programs: Primary Endpoint Achievement Rate is 95% (value provided), and trial dosing completion is shown by Subjects Completing at Least 75 Percent of Planned Dosing (20 count).
  • Z-endoxifen IP support: Patent Claims Covered by Newly Granted United States Patents (Z-Endoxifen) is 31 (count).

Bear case

  • No reported revenue in the latest period: For the period 2026-03-31, revenue is reported as 0.0B.
  • Material operating losses: Operating margin is reported at -3194.2% for the period 2026-03-31.
  • Clinical safety risk remains: Number of Grade 3 Adverse Events is 3 (count), indicating non-zero serious adverse event occurrence in the provided metric set.
Valuation — source: SEC EDGAR (first-party)
Price$2.54
Market Cap$25.30M
Price / Book0.94
Price / Sales17.88
FCF Yield-227.8%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.38M
Net Margin-1462.8%
Revenue Growth (YoY)-41.3%
EPS Growth (YoY)1920.0%
FCF Growth (YoY)41.5%
Financial Health — source: SEC EDGAR
Altman Z-Score-7.25 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($3.63M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSteven C. Quay
Employees15
CountryUS
IPO Date2012-11-08

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • NanoViricides, Inc. (NNVC)
  • Optimi Health Corp. (OPTH)
  • BioXcel Therapeutics, Inc. (BTAI)
  • Aytu BioPharma, Inc. (AYTU)
  • Cellectar Biosciences, Inc. (CLRB)
  • TherapeuticsMD, Inc. (TXMD)
  • ABVC BioPharma, Inc. (ABVC)
  • Marker Therapeutics, Inc. (MRKR)
ATOS earnings history · ATOS institutional & insider holders · ATOS KPIs & operating metrics · ATOS financials · ATOS investor presentations & press releases · ATOS SEC filings · ATOS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.